This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Marx
Nikolaus
University Hospital Aachen, Aachen, Germany

Nikolaus Marx, born in 1968, is Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I, University Hospital Aachen, Germany. He received his medical training at the Universities of Mainz, Genf (Switzerland) and Düsseldorf, obtaining his MD in 1994. His thesis on growth regulation in human renal cancer cell lines was completed at the laboratory of Professor Gerharz at the Institute of Pathology, University of Mainz. After a post-doctoral fellowship with Dr. Peter Libby and Dr. Jorge Plutzky at Brigham and Women's Hospital, Harvard Medical School, Nikolaus Marx later became a board-certified internist, then cardiologist, before specialising in intensive care medicine in internal medicine at the University of Ulm. He was appointed Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I at the University of Aachen in 2009.

Professor Marx is a member of several organisations within the field of cardiology and diabetes, including the European Society of Cardiology, American Heart Association (AHA), German Diabetes Association and the European Association for the Study of Diabetes. In addition to reviewing submitted manuscript to numerous journals, including Circulation, Diabetologia, Diabetes, Diabetes Care, the Journal of Immunology and The Lancet, he is currently Associate Editor for European Heart Journal. Professor Marx was awarded the Servier Young Investigators Award in 1999 at the First European Meeting on Vascular Biology and Medicine, the 2004 Morgagni Young Investigator Award as well as the Rising Star Award 2005 of the European Association for the Study of Diabetes (EASD). Professor Marx has served as President of the German Atherosclerosis Society (DGAF) from 2012 to 2015. He has been a board member of the German Society of Cardiology (DGK) from 05/2017 to 04/2019.

Stephan Jacob

Stephan Jacob

University of Tubingen, Tubingen, Germany


Professor Dr. Stephan Jacob is an endocrinologist/diabetologist, expert in nutrion and a clinical hypertension specialist (ESH). He is teaching at the university of Tuebingen, Germany. He is in private practise and set up a cardio-metabolic institute (CMI), in which non pharmacological and pharmacological therapy life style coaching of cardio-metabolic patients in out-patient care is coordinated, he plans to establish a network with the family doctors and the clinics in his town. Furthermore he is a SCOPE founding fellow and also a member of EASO Collaborating Centre for Obesity Management (EASO-COM).

He is involved in several clinical trials, in obesity, lipid and blood pressure management, specifically the CV outcome trials of new anti-diabetics.

Previously, Dr. Jacob was Senior Consultant at the Department of Endocrinology, Metabolism and Pathobiochemistry, University of Tübingen, Germany.

His research interests include the cardio-metabolic syndrome and the role of early detection and intervention , specifically the effects of life style intervention on prevention and treatment of co-morbidities; to set up structured care in an out-patient setting (CMI).
AND he is convinced that we have to speed up to bring the CHANGE OF PARADIGM in type 2 diabetes management TO THE PEOPLE WITH DIABETES!

Professor Dr. Jacob is in the board of the working group on diabetes and the heart of the german diabetes association. Also he is heading the research group on cardio-metabolic care at the university of Munich. In addition, he has engaged in, bringing the SCOPE program to Germany. Furthermore , he is a member of several guideline committees and editorial boards.


Read full bio
Kausik Ray

Kausik Ray

Imperial College, London, UK


Prof Ray is currently President of the European Atherosclerosis Society, Chair of the World Heart Federation Cholesterol Roadmap 2021 2022, Chair for Global Council for Heart Health. National Lead for CVD N I HR Academic research Collaboration, Clinical Director for Research HDR UK Digital Innovation Hub DISCOVER Now. He received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. His research involves lipids, diabetes and population health serving as global lead for trials and registries. He has >100 000 citations and since 2018 has been recognised annually by Clarivate Analytics as among the top 0.1% of authors in global medicine.

He lead the international development program for Inclisiran, the first siRNA based therapy for cholesterol lowering approved globally , in addition to playing a key role in the development program of Bempedoic A cid and PCSK9 monoclonal antibodies. He initiated the Familial Hypercholesterolaemia Studies Collaboration (FHSC), the only global registry of FH, as well as multinational European registries such as Da Vinci, Heymans and Santorini , all of which are helping to shape global health policy.


Read full bio
Mellbin Linda

Linda Mellbin

Karolinska University Hospital Stockholm, Stockholm, Sweden


Linda Mellbin is Associate Professor of Cardiology and Head of the Coronary Artery Disease Patient Area at Karolinska University Hospital in Stockholm, Sweden.

She obtained her medical degree at Karolinska Institutet in 2000 and, following service at the Department of Medicine at Oskarshamn’s Hospital, she joined the Department of Cardiology at Karolinska University Hospital in 2005. She earned her PhD thesis in 2010 and has thereafter continued research in the field of diabetes and cardiovascular diseases at Karolinska Institutet.

Associate Professor Mellbin has authored several original papers, review articles and book chapters she was project leader for the EAPC (European Association of Preventive Cardiology) Educational Programme on Diabetes and Cardiovascular Disease and she was a member of the European Society of Cardiology Task Force updating the 2013 and 2019 guidelines on diabetes, pre-diabetes and cardiovascular diseases. 


Read full bio